معرفی
Kenneth Micklethwaite is a Lecturer at the University of Sydney's Faculty of Medicine and Health, with departmental affiliation at Westmead Clinical School and the Westmead Institute for Medical Research.
His research focuses on innovative immunotherapies, particularly CAR-T cell development, stem cell transplantation, and pathogen-specific T-cell therapies. Key areas include:
- Engineering CAR-T cells using non-viral methods like piggyBac transposon systems
- Optimizing graft-versus-host disease prophylaxis
- Managing viral reactivations post-transplant
- Developing combination immunotherapies for hematological malignancies
His recent publications demonstrate strong emphasis on improving CAR-T safety/efficacy (e.g., lymphoma risk mitigation), novel manufacturing techniques (e.g., silicon-nanotube transfection), and clinical management guidelines for cellular therapies across 15+ first/last-author papers in high-impact journals.
He actively contributes to national consortia developing next-generation immunotherapies, supported by grants including NHMRC funding for transgenic receptor combinations targeting acute myeloid leukemia and HIV eradication strategies.
